Bionomics begins safety program for cancer antibody
29 July, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has launched IND-enabling pharmacology and toxicology studies for BNC101, its anticancer antibody candidate.
Invion opens phase II trial for chronic bronchitis
26 July, 2013Recruitment has begun for Invion’s phase II trial that aims to repurpose nadolol as a treatment for smoking cessation.
Patrys doses third group in multiple myeloma trial
24 July, 2013Patrys (ASX:PAB) has completed initial treatment for the third of four groups of patients in a phase I/IIa trial of the company’s anticancer antibody, PAT-SM6, in multiple myeloma.
BioDiem progresses liver disease vaccine
24 July, 2013BioDiem (ASX: BDM) has announced its hepatitis vaccine program is making good progress.
New neuroscience facility opens in Sydney
23 July, 2013The new $54 million Neuroscience Research Australia facility has been officially opened in Sydney.
Invion commences phase II clinical trial in lupus
19 July, 2013Invion (ASX:IVX) has commenced patient enrolment in the company’s phase II clinical trial of INV103 in patients with mild systemic lupus erythematosus (lupus).
Viralytics reports strong interim results for cancer treatment
19 July, 2013Interim results look promising for Viralytic’s lead compound Cavatak.
Building Indigenous research capacity
16 July, 2013A new Aboriginal and Torres Strait Islander Researchers’ Network will help to close the higher education gap by supporting aspiring postgraduate and mid-career Aboriginal and Torres Strait Islander researchers.
Rapid test goes to market
09 July, 2013Atomo Diagnostics and BBI Solutions have formed an agreement to commercialise Atomo’s next-generation a rapid blood testing platform.
Prima doubles active sites for cancer vaccine trial
05 July, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has started recruiting for its CANVAS ovarian cancer trial across four more European countries.
HIV treatment could reach millions more people
05 July, 2013HIV-positive people are likely to gain increased access to antiretroviral treatment thanks to research showing that a lower dose is as effective as the standard higher dose.
Invest in science or fall behind
04 July, 2013The Australian Academy of Science has launched its 2013 election policy that calls on the government to work with the science sector to build a long-term strategic vision for Australia’s future.
GI Dynamics raises $57.5m for US diabetes trial
04 July, 2013 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has closed a $57.5m placement and launched an SPP worth up to $2.5m, securing funding for its US trial of EndoBarrier in type 2 diabetes.
Biotron presents HIV trial data at IAS 2013
03 July, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) has presented trial data at International AIDS Society 2013 showing BIT225’s potential to target HIV reservoir cells and cross the blood-brain barrier.
Researching sexual health in Indigenous Australian men
27 June, 2013A PhD scholarship for Aboriginal and Torres Strait Islander students has been created by Andrology Australia.
